Alexion's Rare-Disease Reign Not Over
The biopharma is well positioned with its label expansions and pipeline.
After conducting a deeper dive into the competitive dynamics that Alexion (ALXN) is facing, we’ve lowered our fair value estimate to $169 per share from $172. The shares are still in 4-star territory, however. We think the market is underappreciating Alexion’s invaluable rare-disease expertise and network of patients and doctors, which pose high barriers to entry for branded competitors. The company’s narrow economic moat is underpinned by intangible assets, including patent protection and orphan drug exclusivity with its rare-disease portfolio. We’ve incorporated price headwinds and likely competitor entry into our model, offset by strong volume growth in treatment of generalized myasthenia gravis (approved in 2017) and neuromyelitis optica spectrum disorder (if approved in 2019).
We think Alexion has smartly priced Ultomiris, which was approved in December 2018 and offers a more convenient dosing schedule of six to seven times per year compared with Soliris’ 26 or more infusions per year. By offering it at a slight discount to Soliris, which has an average net annual price of over $450,000 by our estimates, the company should be able to efficiently convert patients to Ultomiris, allowing Alexion to maintain share even as biosimilars and potential branded competitors encroach.
Anna Baran does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.